Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.76 HKD | +3.23% | +20.00% | +10.56% |
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The company's attractive earnings multiples are brought to light by a P/E ratio at 12 for the current year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+10.56% | 238M | - | ||
-18.60% | 3.01B | - | ||
-20.48% | 2.69B | C+ | ||
-61.51% | 1.99B | C- | ||
-42.77% | 174M | - | - | |
-28.49% | 121M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 1846 Stock
- Ratings EuroEyes International Eye Clinic Limited